Louisiana State Employees Retirement System Raises Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Louisiana State Employees Retirement System increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,100 shares of the medical instruments supplier’s stock after acquiring an additional 300 shares during the quarter. Louisiana State Employees Retirement System’s holdings in LeMaitre Vascular were worth $831,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mesirow Institutional Investment Management Inc. purchased a new position in shares of LeMaitre Vascular in the 4th quarter worth about $8,837,000. Congress Asset Management Co. MA boosted its stake in LeMaitre Vascular by 17.0% in the fourth quarter. Congress Asset Management Co. MA now owns 594,672 shares of the medical instruments supplier’s stock valued at $33,754,000 after acquiring an additional 86,293 shares during the last quarter. Summit Creek Advisors LLC grew its position in shares of LeMaitre Vascular by 37.8% during the 4th quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock valued at $12,970,000 after acquiring an additional 62,737 shares during the period. Janus Henderson Group PLC increased its stake in shares of LeMaitre Vascular by 554.7% during the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after purchasing an additional 47,218 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after purchasing an additional 38,303 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Lake Street Capital assumed coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. Roth Mkm restated a “buy” rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a research note on Friday, May 31st. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday. Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Finally, Barrington Research upped their price target on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $90.33.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,030 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The disclosure for this sale can be found here. Insiders have sold a total of 43,251 shares of company stock valued at $3,714,994 in the last 90 days. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Down 0.9 %

Shares of LeMaitre Vascular stock opened at $89.04 on Thursday. The company’s 50-day moving average price is $84.69 and its 200-day moving average price is $75.11. LeMaitre Vascular, Inc. has a 12-month low of $44.27 and a 12-month high of $92.90. The company has a market cap of $2.00 billion, a price-to-earnings ratio of 58.97, a PEG ratio of 2.63 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.63%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.37 EPS. On average, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.72%. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.